293 related articles for article (PubMed ID: 12170449)
1. Docetaxel in the treatment of breast cancer: an update on recent studies.
Nabholtz JM; Reese DM; Lindsay MA; Riva A
Semin Oncol; 2002 Jun; 29(3 Suppl 12):28-34. PubMed ID: 12170449
[TBL] [Abstract][Full Text] [Related]
2. HER2-positive breast cancer: update on Breast Cancer International Research Group trials.
Nabholtz JM; Reese DM; Lindsay MA; Riva A
Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S75-9. PubMed ID: 12435291
[TBL] [Abstract][Full Text] [Related]
3. Ongoing US cooperative group trials using taxanes in the adjuvant setting.
Davidson NE
Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S53-8. PubMed ID: 12435293
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
[TBL] [Abstract][Full Text] [Related]
5. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
Slamon D; Pegram M
Semin Oncol; 2001 Feb; 28(1 Suppl 3):13-9. PubMed ID: 11301370
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Nabholtz JM; Smylie M; Mackey JR; Noel D; Paterson AH; al-Tweigeri T; Au D; Sansregret E; Delorme F; Riva A
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):37-41. PubMed ID: 9364541
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer.
Nabholtz JM; North S; Smylie M; Mackey J; Au HJ; Au R; Morrish D; Salter E; Tonkin K
Semin Oncol; 2000 Apr; 27(2 Suppl 3):11-8. PubMed ID: 10810933
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel: an update of its use in advanced breast cancer.
Figgitt DP; Wiseman LR
Drugs; 2000 Mar; 59(3):621-51. PubMed ID: 10776837
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
Mackey JR; Pieńkowski T; Crown J; Sadeghi S; Martin M; Chan A; Saleh M; Sehdev S; Provencher L; Semiglazov V; Press MF; Sauter G; Lindsay M; Houé V; Buyse M; Drevot P; Hitier S; Bensfia S; Eiermann W
Ann Oncol; 2016 Jun; 27(6):1041-1047. PubMed ID: 26940688
[TBL] [Abstract][Full Text] [Related]
10. [Docetaxel in the adjuvant treatment of operable breast carcinoma. News from ASCO 2002].
Montemurro F
Tumori; 2002; 88(4):A1-7. PubMed ID: 12402832
[No Abstract] [Full Text] [Related]
11. 3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.
Ferreira Filho AF; Crown J; Cardoso F; Nogaret JM; Duffy K; Dolci S; Rowan S; O'Higgins N; Batter V; Paesmans M; Piccart MJ; Di Leo A
Anticancer Res; 2002; 22(4):2471-6. PubMed ID: 12174946
[TBL] [Abstract][Full Text] [Related]
12. [Hungarian experience with docetaxel combination (TAC) in the adjuvant treatment of breast cancer. Results of BCIRG 001 randomized, multicentric, phase III trial].
Boér K; Láng I; Juhos E; Pintér T; Szántó J
Magy Onkol; 2003; 47(2):141-8. PubMed ID: 12975660
[TBL] [Abstract][Full Text] [Related]
13. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
Chan S; Friedrichs K; Noel D; Pintér T; Van Belle S; Vorobiof D; Duarte R; Gil Gil M; Bodrogi I; Murray E; Yelle L; von Minckwitz G; Korec S; Simmonds P; Buzzi F; González Mancha R; Richardson G; Walpole E; Ronzoni M; Murawsky M; Alakl M; Riva A; Crown J;
J Clin Oncol; 1999 Aug; 17(8):2341-54. PubMed ID: 10561296
[TBL] [Abstract][Full Text] [Related]
14. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Sparano JA
Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel and anthracycline polychemotherapy in the treatment of breast cancer.
Nabholtz JM; Smylie M; Mackey J; Au HJ; Tonkin K; Au R; Morrish D; Salter E
Semin Oncol; 1999 Jun; 26(3 Suppl 8):47-52. PubMed ID: 10403474
[TBL] [Abstract][Full Text] [Related]
16. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
Guarneri V; Frassoldati A; Bruzzi P; D'Amico R; Belfiglio M; Molino A; Bertetto O; Cascinu S; Cognetti F; Di Leo A; Pronzato P; Crinó L; Agostara B; Conte P
Clin Breast Cancer; 2008 Oct; 8(5):453-6. PubMed ID: 18952561
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin).
Burris HA
Semin Oncol; 2000 Apr; 27(2 Suppl 3):19-23. PubMed ID: 10810934
[TBL] [Abstract][Full Text] [Related]
18. [Role of taxanes in treatment of breast cancer].
Gorbunova VA; Besova NS
Vopr Onkol; 2004; 50(4):492-500. PubMed ID: 15605777
[No Abstract] [Full Text] [Related]
19. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
Nabholtz JM; Falkson C; Campos D; Szanto J; Martin M; Chan S; Pienkowski T; Zaluski J; Pinter T; Krzakowski M; Vorobiof D; Leonard R; Kennedy I; Azli N; Murawsky M; Riva A; Pouillart P;
J Clin Oncol; 2003 Mar; 21(6):968-75. PubMed ID: 12637459
[TBL] [Abstract][Full Text] [Related]
20. Expanding options in breast cancer.
Crown JP
Anticancer Drugs; 1999 Nov; 10 Suppl 1():S19-24. PubMed ID: 10630364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]